This article is more than 5 years old. Information may no longer be current.
Top meeting news of 2019
Click Here to Manage Email Alerts
Endocrine Today has compiled a list of the top 10 news reports posted from meeting news coverage during the first few months of 2019.
Healio.com/Endocrinology readers were interested in updated diabetes treatment guidelines, agents that can disrupt thyroid hormone metabolism, new testosterone options and much more.
New guideline emphasizes simpler diabetes regimens, looser glycemic targets for older adults Endocrine Society Annual Meeting
Treatment of diabetes in older adults remains a challenge, and a new guideline from the Endocrine Society recommends simplified medication regimens and looser glycemic targets to improve adherence and prevent treatment-related complications in this patient population.
Supplements, cancer therapies, endocrine-disrupting chemicals can alter thyroid function AACE Annual Scientific and Clinical Congress
Medications, supplements, excessive iodine intake and other exogenous substances, including endocrine-disrupting chemicals, can influence multiple thyroid effects that clinicians should recognize.
New testosterone therapies offer options for men with hypogonadism Androgen Society annual meeting
Three new testosterone therapies offer innovative drug delivery options for men with hypogonadism that improve patient satisfaction while avoiding risks related to secondary exposure.
Beyond calcium, vitamin D, supplements may do more harm than good for bones AACE Annual Scientific and Clinical Congress
When it comes to optimal bone health and fracture prevention, there is scant evidence for recommending supplementation with vitamins and minerals other than calcium and vitamin D.
Testosterone improves libido, quality of life in women with low sexual desire Androgen Society annual meeting
Premenopausal and postmenopausal women reporting a persistent, low libido that profoundly impairs quality of life can experience an improvement in symptoms with transdermal testosterone, but clinicians must consider several important points before prescribing the therapy.
Testosterone therapy reduces CV events, death in men with hypogonadism Androgen Society annual meeting
Low testosterone is associated with increased all-cause and cardiovascular mortality, and testosterone replacement therapy in men with a confirmed diagnosis of hypogonadism is associated with reduced CV events and CV death.
Antimalarial drug effective alternative to canagliflozin in type 2 diabetes AACE Annual Scientific and Clinical Congress
Adults with type 2 diabetes inadequately controlled with a DPP-IV inhibitor plus metformin therapy experienced an improvement in glycemic control with the antimalarial drug hydroxychloroquine that was similar to the SGLT2 inhibitor canagliflozin.
Estradiol level influences telomere length in older men Endocrine Society Annual Meeting
Older men with a higher estradiol level were more likely to have longer telomeres associated with so-called biological age, independent of lifestyle factors and comorbidities.
Cardiologists see more patients with type 2 diabetes than endocrinologists Endocrine Society Annual Meeting
Adults with type 2 diabetes and cardiovascular disease receive outpatient care from cardiologists more often than from endocrinologists, especially when CVD is also present.
Gut microbiome could hold key for PCOS treatment Endocrine Society Annual Meeting
Adjustments targeting specific bacteria in the gut microbiome may be an effective strategy for treating polycystic ovary syndrome.